M
myNEO Therapeutics develops breakthrough immunotherapies by leveraging its ImmunoEngine platform to identify novel tumor targets called camyotopes from the dark genome. These targets are specifically translated in cancer cells, offering the potential to expand immunotherapy response to broader patient populations. The company focuses on creating off-the-shelf treatments by unlocking first-in-class targets that mitigate immune escape.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- myNEO Therapeutics develops breakthrough immunotherapies by leveraging its ImmunoEngine platform to identify novel tumor targets called camyotopes from the dark genome. These targets are specifically translated in cancer cells, offering the potential to expand immunotherapy response to broader patient populations. The company focuses on creating off-the-shelf treatments using these first-in-class targets to improve therapeutic efficacy.